Skip to main content

Table 3 The 46 most common ART regimens purchased in 2016, by regimen categorya

From: HIV treatment regimens and adherence to national guidelines in Australia: an analysis of dispensing data from the Australian pharmaceutical benefits scheme

Regimen categoryb N = 1786 n (%)
Category 1: Guideline recommended regimens 998 (55.9)
 dolutegvravir/abacavir/lamivudine 419 (42.0)
 elvitegravir/cobicistat/TAF/emtricitabine 256 (25.7)
 dolutegravir + [TDF/emtricitabine or TAF/emtricitabine] 146 (14.6)
 raltegravir + [TDF/emtricitabine or TAF/emtricitabine] 89 (8.9)
 elvitegravir/cobicistat/TDF/emtricitabine 61 (6.1)
 r/darunavir + [TDF/emtricitabine or TAF/emtricitabine] 27 (2.7)
Category 2: Guideline alternative regimens 448 (25.1)
 efavirenz/TDF/emtricitabine 207 (46.2)
 rilpivirine/TDF/emtricitabine 190 (42.4)
 [r/atazanavir or c/atazanavir] + [TDF/emtricitabine or TAF/emtricitabine] 44 (9.8)
 [c/darunavir or r/darunavir] + abacavir/lamivudine 7 (1.6)
 c/darunavir + [TDF/emtricitabine or TAF/emtricitabine] 0
 efavirenz + TAF/emtricitabine 0
 rilpivirine/TAF/emtricitabine 0
Category 3: Guideline other regimens 48 (2.7)
 raltegravir + abacavir/lamivudine 15 (31.3)
 efavirenz + abacavir/lamivudine 14 (29.2)
 r/darunavir + raltegravirc 11 (22.9)
 [r/atazanavir or c/atazanavir] + abacavir/lamivudine 8 (16.7)
 lopinavir/ritonavir + lamivudinec 0
Category 4: Other combinations of guideline-recommended ART 89 (5.0)
 r/darunavir + dolutegravir 15 (16.9)
 r/darunavir + raltegravir + TDF/emtricitabine 13 (14.6)
 elvitegravir/cobicistat/TAF/emtricitabine + darunavir 10 (11.2)
 r/lopinavir + TDF/emtricitabine 9 (10.1)
 dolutegravir/abacavir/lamivudine + TDF 7 (7.8)
 TDF/emtricitabine alone 6 (6.7)
 elvitegravir/cobicistat/TAF/emtricitabine + atazanavir 4 (4.5)
 r/darunavir + lamivudine 4 (4.5)
 r/atazanavir + abacavir/lamivudine + TDF 3 (3.4)
 dolutegravir/abacavir/lamivudine + r/darunavir 3 (3.4)
 r/darunavir + dolutegravir + lamivudine 3 (3.4)
 dolutegravir + rilpivirine + lamivudine 3 (3.4)
 dolutegravir + rilpivirine 3 (3.4)
 r/darunavir alone 3 (3.4)
 r/darunavir + dolutegravir + TDF/emtricitabine 3 (3.4)
Category 5: Medications not recommended for first-line ART regimens but used in special circumstances 203 (11.4)d
 nevirapine-containing regimend 157
 etravirine-containing regimen 20
 unboosted atazanavir or darunavir-containing regimen 18
 zidovudine/lamivudine-containing regimenc 16
 maraviroc-containing regimen 4
 tipranavir-containing regimen 0
 enfurvitide-containing regimen 0
  1. aThis table excludes category six which is reported in the text
  2. bRegimens were grouped together if containing the same individual antiviral agents; for example, the combination tablet dolutegravir/abacavir/lamivudine was grouped with regimens of dolutegravir plus the combination tablet abacavir/lamivudine and with regimens of the three individual medications dolutegravir plus abacavir plus lamivudine, if prescribed separately
  3. cRecommended for use only when TAF, TDF or ABC cannot be used
  4. dTotal number of persons purchasing any antiretroviral listed in category five. Twelve people were purchasing both nevirapine and zidovudine/lamivudine; therefore, 203 persons were purchasing 215 medications in category five